Want to see KR:000220 full AI Analyst Report?
Top Page
Yuyu Pharma, Inc.
(000220)
Select Model
Select Model
Rating:66Neutral
Price Target:
₩3,964.00
Action:N/A
Date:10/28/26
The score is primarily supported by improved financial fundamentals (return to profitability and a conservative balance sheet) and very attractive valuation (low P/E and a solid dividend yield). This is offset by weak technicals, with the stock below major moving averages and negative MACD, suggesting near-term momentum remains soft despite oversold signals.
Positive Factors
Profitability Recovery
Net income turned solidly positive in 2024–2025 and remained strong in TTM, showing meaningful recovery from losses. If maintained, this improves internal funding capacity and supports reinvestment, financial resilience, and more durable earnings power over the medium term.
Negative Factors
Inconsistent Operating Profitability
Material variation in operating and EBITDA margins makes the recent earnings recovery less predictable than the headline net income improvement suggests. Uneven cost absorption, product mix, or other period-specific effects could limit the durability of operating profits.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Recovery
Net income turned solidly positive in 2024–2025 and remained strong in TTM, showing meaningful recovery from losses. If maintained, this improves internal funding capacity and supports reinvestment, financial resilience, and more durable earnings power over the medium term.
Read all positive factors
Yuyu Pharma, Inc. (000220) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩53.37B
Dividend Yield3.12%
Average Volume (3M)42.52K
Price to Earnings (P/E)4.9
Beta (1Y)0.13
Revenue Growth6.69%
EPS Growth220.70%
CountryKR
Employees248
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)746.40
Shares Outstanding15,747,462
10 Day Avg. Volume47,184
30 Day Avg. Volume42,522
Financial Highlights & Ratios
PEG Ratio1.80
Price to Book (P/B)0.58
Price to Sales (P/S)0.53
P/FCF Ratio9.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Yuyu Pharma, Inc. Business Overview & Revenue Model
Company Description
Yuyu Pharma, Inc. specializes in the development and commercialization of pharmaceutical products. Its extensive portfolio of prescription medications addresses a wide range of conditions, including osteoporosis, disorders related to brain-bone me...
Yuyu Pharma, Inc. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 144.37B | 140.88B | 133.15B | 137.21B | 138.88B | 115.66B |
| Gross Profit | 55.10B | 53.94B | 51.70B | 48.53B | 53.31B | 45.34B |
| EBITDA | 9.60B | 16.63B | 18.87B | 4.86B | 3.40B | 6.30B |
| Net Income | 12.50B | 8.15B | 8.72B | -7.18B | -4.43B | -920.29M |
Balance Sheet | ||||||
| Total Assets | 207.88B | 207.22B | 207.69B | 198.21B | 195.21B | 192.99B |
| Cash, Cash Equivalents and Short-Term Investments | 27.86B | 29.09B | 42.65B | 32.35B | 30.78B | 50.26B |
| Total Debt | 28.06B | 27.92B | 33.64B | 39.41B | 39.28B | 39.17B |
| Total Liabilities | 61.70B | 67.04B | 72.62B | 77.86B | 71.83B | 64.30B |
| Stockholders Equity | 134.79B | 129.28B | 125.23B | 112.19B | 116.82B | 124.28B |
Cash Flow | ||||||
| Free Cash Flow | 5.78B | 7.81B | 17.65B | -4.69B | -11.80B | -2.24B |
| Operating Cash Flow | 20.91B | 16.07B | 24.95B | 420.86M | -6.23B | 4.51B |
| Investing Cash Flow | -22.32B | -13.15B | -4.01B | -2.81B | -8.54B | -5.89B |
| Financing Cash Flow | -6.95B | -15.90B | -9.86B | 7.16B | -9.08B | 31.31B |
Yuyu Pharma, Inc. Technical Analysis
Negative
―
Price Trends
3784.20
Negative
3757.45
Negative
4022.32
Negative
Market Momentum
-31.41
Positive
44.94
Neutral
18.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:000220, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 3742.00, equal to the 50-day MA of 3784.20, and equal to the 200-day MA of 4022.32, indicating a bearish trend. The MACD of -31.41 indicates Positive momentum. The RSI at 44.94 is Neutral, neither overbought nor oversold. The STOCH value of 18.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:000220.
Yuyu Pharma, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₩53.37B | 4.90 | ― | 3.12% | 6.69% | 220.70% | |
60 Neutral | ₩404.42B | 8.96 | ― | 1.56% | -0.65% | ― | |
58 Neutral | ₩144.41B | 7.86 | ― | 4.70% | 6.59% | 185.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₩299.64B | 12.56 | ― | 1.57% | 5.50% | -26.11% | |
50 Neutral | ₩369.99B | 64.89 | ― | 3.33% | 22.17% | -38.54% | |
47 Neutral | ₩167.66B | -4.41 | ― | 0.96% | -4.54% | -88.02% |
* General Sector Average
KR:000220
Yuyu Pharma, Inc.
3,690.00
-364.30
-8.99%
KR:000020
Dong Wha Pharm Co., Ltd.
5,210.00
-950.90
-15.43%
KR:000520
Samil Pharmaceutical Co., Ltd.
7,780.00
-1,440.00
-15.62%
KR:003000
Bukwang Pharmaceutical Co., Ltd.
3,750.00
177.39
4.97%
KR:009290
Kwang Dong Pharmaceutical Co., Ltd.
6,370.00
705.94
12.46%
KR:249420
Ildong Pharmaceutical Co., Ltd.
12,790.00
-9,511.57
-42.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.